The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
Subscribe To Our Newsletter & Stay Updated
